Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Free Cash Flow (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Free Cash Flow for 6 consecutive years, with -$10.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 43.17% year-over-year to -$10.4 million, compared with a TTM value of -$29.5 million through Dec 2025, up 39.53%, and an annual FY2025 reading of -$29.5 million, up 39.53% over the prior year.
  • Free Cash Flow was -$10.4 million for Q4 2025 at Treace Medical Concepts, up from -$11.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $655000.0 in Q1 2025 and bottomed at -$18.7 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$9.5 million, with a median of -$10.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 1252.18% in 2022, then skyrocketed 105.88% in 2025.
  • Year by year, Free Cash Flow stood at -$4.7 million in 2021, then tumbled by 65.31% to -$7.7 million in 2022, then skyrocketed by 77.69% to -$1.7 million in 2023, then crashed by 324.3% to -$7.3 million in 2024, then plummeted by 43.17% to -$10.4 million in 2025.
  • Business Quant data shows Free Cash Flow for TMCI at -$10.4 million in Q4 2025, -$11.9 million in Q3 2025, and -$7.8 million in Q2 2025.